TCGA-69-7764-01A-11R-2170-07
— · cohortA2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA2
- subtype
- cohortA2
- age_years
- 75
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.170
- TGF_BETA_SIGNALING+0.160
- BILE_ACID_METABOLISM+0.140
- PEROXISOME+0.100
- ANDROGEN_RESPONSE+0.080
- HEME_METABOLISM+0.070
- MYOGENESIS+0.060
- KRAS_SIGNALING_DN+0.050
- WNT_BETA_CATENIN_SIGNALING+0.040
- CHOLESTEROL_HOMEOSTASIS+0.030
Top 10 suppressed
- E2F_TARGETS-0.460
- MTORC1_SIGNALING-0.440
- MYC_TARGETS_V2-0.390
- G2M_CHECKPOINT-0.350
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.350
- MYC_TARGETS_V1-0.340
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.310
- INFLAMMATORY_RESPONSE-0.300
- OXIDATIVE_PHOSPHORYLATION-0.290
- UNFOLDED_PROTEIN_RESPONSE-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3L-02958 | — | cohortA1 | 0.907 |
| 2 | TCGA-55-8097-01A-11R-2241-07 | — | cohortA1 | 0.897 |
| 3 | C3L-00893 | — | cohortA1 | 0.897 |
| 4 | SRR6013544 | — | cohortA1 | 0.884 |
| 5 | C3N-02973 | — | cohortA1 | 0.880 |
| 6 | TCGA-95-A4VK-01A-11R-A262-07 | — | cohortA4 | 0.875 |
| 7 | C3N-02950 | — | cohortA1 | 0.875 |
| 8 | SRR1516060 | — | — | 0.875 |
| 9 | C3N-03420 | — | cohortA1 | 0.872 |
| 10 | 3ca8899d-3ed3-478b-a70c-919f68969d81 | — | — | 0.871 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.170 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.160 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.080 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.070 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.060 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.050 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.040 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.030 | Remibrutinib | — uncovered |
| COAGULATION | 0.030 | Binimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |